Treatment of individuals with type 1 diabetes with alefacept (a lymphocyte function-associated antigen-3 immunoglobulin [LFA-3Ig] fusion protein that binds to CD2 and depletes T cells displaying high levels of this surface antigen) significantly decreased dependency on exogenous insulin 24 months after treatment [55]. This evidence concerns the gene INS and type 1 diabetes mellitus.